Research and Clinical Trials from
Charles Retina Institute
Research
Charles Retina Institute offers a gateway to the frontiers of research and development in the field of retinal care. Pharmaceutical and surgical companies turn to our physicians to serve as primary investigators for their studies in the development of treatments for ocular conditions including macular degeneration, diabetic retinopathy, ocular occlusive diseases, and genetic therapies.
Within the framework of our institute, we have an independent research department that allows us to screen patients for eligibility in a multitude of new and innovative therapeutic studies. Upon completion of the study specific screening process, patients meeting the required criteria will be eligible for enrollment.
Current Studies
Diabetic Macular Edema
GE43828 (active, enrolling)
A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections OF RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema
ML43435 (active, enrolling)
A Phase IIIB/IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients with Diabetic Macular Edema (ELEVATUM)
MR41926 (active, enrolling)
An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients with Diabetic Macular Edema Treated with Faricimab (RO6867461) (ALTIMETER)
Diabetic Retinopathy:
KS301P106 (active, enrolling)
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW)
RGX-314-2202 (active, enrolling)
A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Diabetic Retinopathy (DR) without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)
Intermediate Age-Related Macular Degeneration:
GE43220 (active, enrolling)
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Neurovascular Age-Related Macular Degeneration:
GE43341 (active, enrolling)
A prospective, observational, post-marketing surveillance study to monitor the safety of the port delivery system with ranibizumab in patients with neovascular age-related macular Degeneration (VILLA)
RGX-314-2102 (active, enrolling)
A Phase 2a, Open-label, Randomized, Ranibizumab control, Dose-escalation Study to Evaluate the Efficacy, Safety and Tolerability of RGX-314 Gene Therapy Administered in the Suprachoroidal Space (SCS) to Participants with Neovascular AMD (nAMD) (AVIATE)
RGX-314-2103 (active, enrolling)
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with Neovascular Age-related Macular Degeneration
RGX-314-2104 (active, enrolling)
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
RGX-314-3101 (active, enrolling)
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Wet Age-Related Macular Degeneration
EYP-1901-201 (active, enrolling)
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
For additional information, please contact our Clinical Research Manager, Molly Scott, at
(901) 683-0399, ext. 242 or at mscott@charlesretina.com.